🇺🇸 Conversion at day 7 ± 3 Prograf® to Advagraf® in United States

Conversion at day 7 ± 3 Prograf® to Advagraf® (Conversion at day 7 ± 3 Prograf® to Advagraf®) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Conversion at day 7 ± 3 Prograf® to Advagraf® in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Conversion at day 7 ± 3 Prograf® to Advagraf® approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Conversion at day 7 ± 3 Prograf® to Advagraf® in United States?

Assistance Publique - Hôpitaux de Paris is the originator. The local marketing authorisation holder may differ — check the official source linked above.